International Clinical Trial: Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07725406) titled 'Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma' on July 21.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Weill Medical College of Cornell University

Condition: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Relapsed or Refractory Multiple Myeloma (MM)

Intervention: Drug: Lymphodepleting chemotherapy: Cyclophosphamide Drug: Lymphodepleting chemotherapy: Bendamustine Drug: Lymphodepleting chemotherapy: Fludarabine Other: L...